Previous 10 | Next 10 |
Gainers: Ascendis Pharma (NASDAQ:ASND) +25%, Zomedica (NYSE:ZOM) +15%, ABVC BioPharma (OTCQB:ABVC) +15%, BeyondSpring (NASDAQ:BYSI) +13%, Cortexyme (NASDAQ:CRTX) +12%. Losers: Aditxt (NASDAQ:ADTX) -29%, Quanterix (NASDAQ:QTRX) -12%, Doxim...
Fremont, CA - ( NewMediaWire ) - August 26, 2021 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update regarding recent developments in connection with Vitarg...
FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update regarding recent development...
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) ...
Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense research and development activities opposing dangerous disease...
Gainers: Trillium Therapeutics TRIL +189%. Vivos Therapeutics VVOS +49%. ABVC BioPharma (OTCQB:ABVC) +29%. Pixelworks (NASDAQ:PXLW) +25%. LightInTheBox (NYSE:LITB) +27%. Canoo GOEV +25%. City Office CIO +25%. Equillium (NASDAQ:EQ) +24%. Endo International plc (NASDAQ...
Gainers: NanoVibronix (NASDAQ:NAOV) +27%, Apyx Medical (NASDAQ:APYX) +20%, Xenetic Biosciences (NASDAQ:XBIO) +19%, Doximity (NYSE:DOCS) +15%, OncoCyte (NASDAQ:OCX) +14%. Losers: MedAvail (NASDAQ:MDVL) -51%, LifeStance Health (NASDAQ:LFST) -49%...
MedAvail Holdings MDVL -34% on Q2 earnings release LifeStance Health LFST -24% on Q2 earnings release GoHealth GOCO -17% on Q2 earnings release VYNE Therapeutics VYNE -15% on Q2 earnings release and after BET inhibitor licensing deal with In4d...
Clinical Trials Continue Despite COVID-19 Restrictions Fremont, CA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous syste...
CohBar (NASDAQ:CWBR) +62% on Q2 earnings Good Times Restaurant (NASDAQ:GTIM) +32% on Q3 earnings Upstart Holdings (NASDAQ:UPST) +22% on Q2 earnings Mogo (NASDAQ:MOGO) +20% on Q2 earnings fuboTV (NYSE:FUBO) +16% on Q2 earnings Lantern Pharma (N...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
FREMONT, CA - ( NewMediaWire ) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...
FREMONT, CA - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...